Adaptive Biotechnologies (NASDAQ:ADPT) Issues Earnings Results

Adaptive Biotechnologies (NASDAQ:ADPT) posted its earnings results on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03, FiscalAI reports. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The company had revenue of $70.87 million for the quarter, compared to analysts’ expectations of $61.03 million. During the same period last year, the firm earned ($0.20) earnings per share. Adaptive Biotechnologies’s quarterly revenue was up 35.1% on a year-over-year basis.

Here are the key takeaways from Adaptive Biotechnologies’ conference call:

• MRD momentum and guidance — MRD revenue grew 53% year‑over‑year to $67.1M in Q1 and management raised full‑year MRD revenue guidance to $260M–$270M (includes a $9M milestone recognized in Q1).
• Margin and profitability progress — sequencing gross margin expanded to 70% (up 8 pts YoY) and MRD delivered positive adjusted EBITDA of $12.1M, with the company targeting >70% sequencing gross margins and positive adjusted EBITDA and free cash flow by end of 2026.
• Biopharma validation and backlog — bookings drove a pharma backlog of about $254M (up 24% YoY), including registrational studies and the company’s first recognized primary‑endpoint milestone (CEPHEUS), signaling stronger, higher‑value pharma demand for MRD endpoints.
• Clinical adoption and reimbursement traction — clonoSEQ set a quarterly volume record (~632,600 tests), blood‑based testing rose to 49% of MRD volume, community testing grew 67% YoY to 35% of volumes, U.S. ASPs increased 11% to $1,360, and clonoSEQ was listed in the Texas Medicaid Policy Manual.
• Immune Medicine remains a drag — Immune Medicine revenue fell 26% to $3.8M with an adjusted EBITDA loss of $10.4M, and management expects IM cash burn of $15M–$20M for 2026 while commercialization/partnerships are still being developed.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ ADPT traded down $0.72 on Tuesday, reaching $13.78. 3,176,459 shares of the company’s stock traded hands, compared to its average volume of 1,541,203. The business’s 50 day simple moving average is $14.32 and its two-hundred day simple moving average is $15.92. Adaptive Biotechnologies has a 12 month low of $8.38 and a 12 month high of $20.76.

Insiders Place Their Bets

In other news, COO Julie Rubinstein sold 19,037 shares of Adaptive Biotechnologies stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $14.23, for a total value of $270,896.51. Following the completion of the transaction, the chief operating officer owned 377,802 shares of the company’s stock, valued at $5,376,122.46. The trade was a 4.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chad M. Robins sold 37,263 shares of the company’s stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $15.19, for a total value of $566,024.97. Following the completion of the transaction, the chief executive officer directly owned 2,180,518 shares in the company, valued at $33,122,068.42. This trade represents a 1.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 2,419,313 shares of company stock worth $34,192,596. Insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Adaptive Biotechnologies

Hedge funds have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. bought a new position in Adaptive Biotechnologies in the 4th quarter worth $51,000. Strive Financial Group LLC bought a new position in shares of Adaptive Biotechnologies in the fourth quarter worth about $52,000. Caxton Associates LLP purchased a new stake in shares of Adaptive Biotechnologies during the first quarter worth about $93,000. Persistent Asset Partners Ltd bought a new stake in Adaptive Biotechnologies during the 4th quarter valued at approximately $109,000. Finally, Quadrant Capital Group LLC purchased a new position in Adaptive Biotechnologies in the 3rd quarter worth approximately $133,000. 99.17% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Guggenheim raised their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, January 26th. JPMorgan Chase & Co. lifted their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $19.43.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.